Abstract
Introduction

Rhabdomyolysis is a clinical and biochemical syndrome resulting from skeletal muscle injury and the release of muscle cell constituents into the circulation. It may result in myoglobinuria, the filtration of myoglobin into the urine, and it is often associated with acute renal failure (1). Druginduced rhabdomyolysis occurs rarely and may be asymptomatic. However, life-threatening severe electrolyte disorders and acute renal failure may occur in the more serious cases (2). Rhabdomyolysis results from inherited muscle enzyme deficiencies, toxins such as alcohol abuse and cocaine, trauma, drugs such as statins, muscle overexertion, infections, and other disorders (3)
.
Discussion
Fenofibrate is a drug of the fibrate class that reduces very low density lipoprotein (VLDL), triglycerides, and low density lipoprotein (LDL) and increases high density lipoprotein (HDL). Its adverse effects such as skin reactions, blood disturbances (except for muscle and hepatic side effects) are tolerable and reversible (8). The most important side effect of fenofibrate is rhabdomyolysis (9).
In patients who have high serum cholesterol and triglycerides, with only simple statin or fibrate treatment, it is difficult to decrease both serum LDL-cholesterol and triglycerides. In such patients, especially if they have high-risk of coronary artery disease or already have coronary artery disease, with combined treatment with statin and fibrate, recommend target lipid levels are achieved. However, adverse effects such as myopathy, hepatic injury, and rhabdomyolysis of the combination treatment may develop in some patients (7, 10) .
In the study of Schech et al., older age (!65) was a risk factor for rhabdomyolysis among statin users. Also high statin dosage and renal disease were related to an increased risk for rhabdomyolysis (11 (12) . Fenofibrate-induced rhabdomyolysis in patients with hypothyroidism has been previously reported (10, 12) . In the present patients who developed rhabdomyolysis, the thyroid function tests and anti-TPO antibody titer were normal.
In addition, five patients with polymyositis related to lipid-lowering agents including statin and fenofibrate have been reported (13 
